tm logo
KANNALIFE
Dead/Abandoned
ABANDONED - NO STATEMENT OF USE FILED

no statement of use filed

on 11 May 2015

Last Applicant/ Owned by

363 West Hills Road

West Hills

NY

11743

Serial Number

86034690 filed on 12th Aug 2013

Registration Number

N/A

Correspondent Address

Brad M. Behar

Brad M. Behar

94 Second Street

Mineola NY 11501

Filing Basis

1. intent to use current

Disclaimer

NO DATA

KANNALIFE

Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Homeopathic pharmaceuticals for use in the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Inhalers filled with naturopathic and/or pharmaceutical products for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Pharmaceutical agents affecting digest Read More

Classification Information


Class [001]
Chemical Products


Active chemical ingredients for use in the manufacture of pharmaceuticals for treating Oxidative Stress Related and Neurodegenerative Diseases; Chemical additives for use in the manufacture of naturopathic and/or pharmaceutical products for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Emollient used as an ingredient in the manufacture of cosmetics, toiletries, and pharmaceuticals

Class [005]
Pharmaceutical Products


Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Homeopathic pharmaceuticals for use in the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Inhalers filled with naturopathic and/or pharmaceutical products for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents for epidermis; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention of Oxidative Stress Related and Neurodegenerative Diseases; Pharmaceutical preparations for the treatment and prevention of Oxidative Stress Related and Neurodegenerative Diseases; Pharmaceutical preparations for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Pharmaceutical preparations, namely, elixirs for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical skin lotions; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, psychotropics; Plant extracts for medical, veterinary and pharmaceutical purposes; Sunburn preparations for pharmaceutical purposes; Syringes sold filled with naturopathic and/or pharmaceutical products for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Syrups for pharmaceutical purposes for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Therapeutic pharmaceutical for the treatment of Oxidative Stress Related and Neurodegenerative Diseases

Class [042]
Computer & Software Services & Scientific Services


Conducting early evaluations in the field of new pharmaceuticals; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Development of pharmaceutical preparations and medicines; Laboratory research services relating to pharmaceuticals; Pharmaceutical products development; Pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research in the field of Oxidative Stress Related and Neurodegenerative Diseases

Mark Details


Serial Number

No 86034690

Mark Type

No Service Mark

Attorney Docket Number

No 13026/0010

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
11th May 2015ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
11th May 2015ABANDONMENT - NO USE STATEMENT FILED
07th Oct 2014NOA E-MAILED - SOU REQUIRED FROM APPLICANT
13th Aug 2014ASSIGNED TO EXAMINER
12th Aug 2014PUBLISHED FOR OPPOSITION
12th Aug 2014OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11th Aug 2014ASSIGNED TO EXAMINER
23rd Jul 2014NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08th Jul 2014LAW OFFICE PUBLICATION REVIEW COMPLETED
07th Jul 2014APPROVED FOR PUB - PRINCIPAL REGISTER